Insider transactions

EDGAR

PHATHOM PHARMACEUTICALS, INC.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-20.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
0 transactions, — shares

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–45 of 45

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-10-06 Filed 2026-10-08Narula Sanjeev Officer: Chief Financial Bus. Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)13,4856.78
91,428.3

Derived: shares × price per share. Exact value 91428.30.

214,718Direct (D) No
F1, F2
  • F1 Represents shares underlying the restricted stock units that were surrendered by the reporting person to the Issuer in satisfaction of the Issuer's tax withholding obligation.
  • F2 Includes 1,488 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in July 2026.
Open filing 0001193125-26-418114 Read from the filing’s XML Dispute this row
2026-09-03 Filed 2026-09-08Breedlove Robert Charles Officer: Principal Accounting Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)4609.05
4,163

Derived: shares × price per share. Exact value 4163.00.

59,465Direct (D) No
F1
  • F1 Represents shares underlying the restricted stock units that were surrendered by the reporting person to the Issuer in satisfaction of the Issuer's tax withholding obligation.
Open filing 0001193125-26-385250 Read from the filing’s XML Dispute this row
2026-07-14 Filed 2026-07-16Breedlove Robert Charles Officer: Principal Accounting Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)1,55511.035
17,159.425

Derived: shares × price per share. Exact value 17159.425.

59,925Direct (D) No
F1
  • F1 Represents shares underlying the restricted stock units that were surrendered by the reporting person to the Issuer in satisfaction of the Issuer's tax withholding obligation.
Open filing 0001193125-26-306165 Read from the filing’s XML Dispute this row
2026-05-22 Filed 2026-05-27Parikh Asit Director
G

Bona fide gift

Common Stock
Disposed (D)28,0000—24,122Direct (D) No— Open filing 0001193125-26-241984 Read from the filing’s XML Dispute this row
2026-05-22 Filed 2026-05-27Parikh Asit Director
G

Bona fide gift

Common Stock
Acquired (A)28,0000—148,500Indirect (I) by TrustNo
F1
  • F1 Reflects shares transferred for no consideration to a trust for the benefit of the Reporting Person's spouse and for which the Reporting Person serves as trustee.
Open filing 0001193125-26-241984 Read from the filing’s XML Dispute this row
2026-05-20 Filed 2026-05-21Parikh Asit Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)17,5004.95
86,625

Derived: shares × price per share. Exact value 86625.00.

52,122Direct (D) No— Open filing 0001193125-26-234891 Read from the filing’s XML Dispute this row
2026-05-20 Filed 2026-05-21Parikh Asit Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Common Stock (Right to Buy) — underlying Common Stock (17,500) — exercise price 4.95
Disposed (D)17,5000—0Direct (D) No— Open filing 0001193125-26-234891 Read from the filing’s XML Dispute this row
2026-05-19 Filed 2026-05-21Schroeder Theodore R Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)24,1220—45,122Direct (D) No
F1
  • F1 The Restricted Stock Units (RSUs) were granted on May 19, 2026, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
Open filing 0001193125-26-234563 Read from the filing’s XML Dispute this row
2026-05-19 Filed 2026-05-21Stenhouse Mark Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)24,1220—54,122Direct (D) No
F1
  • F1 The Restricted Stock Units (RSUs) were granted on May 19, 2026, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
Open filing 0001193125-26-234568 Read from the filing’s XML Dispute this row
2026-05-19 Filed 2026-05-21KARBE FRANK Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)24,1220—91,622Direct (D) No
F1
  • F1 The Restricted Stock Units (RSUs) were granted on May 19, 2026, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
Open filing 0001193125-26-234564 Read from the filing’s XML Dispute this row
2026-05-19 Filed 2026-05-21Parikh Asit Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)24,1220—34,622Direct (D) No
F1
  • F1 The Restricted Stock Units (RSUs) were granted on May 19, 2026, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
Open filing 0001193125-26-234891 Read from the filing’s XML Dispute this row
2026-05-19 Filed 2026-05-21FIELDS HEIDI Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)24,1220—54,122Direct (D) No
F1
  • F1 The Restricted Stock Units (RSUs) were granted on May 19, 2026, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
Open filing 0001193125-26-234567 Read from the filing’s XML Dispute this row
2026-05-19 Filed 2026-05-21COLA MICHAEL F Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)24,1220—63,920Direct (D) No
F1
  • F1 The Restricted Stock Units (RSUs) were granted on May 19, 2026, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
Open filing 0001193125-26-234566 Read from the filing’s XML Dispute this row
2026-05-19 Filed 2026-05-21Topper James N Director · 10% owner
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)24,1220—66,718Direct (D) No
F1
  • F1 The Restricted Stock Units (RSUs) were granted on May 19, 2026, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
Open filing 0001193125-26-234572 Read from the filing’s XML Dispute this row
2026-03-10 Filed 2026-03-11Parikh Asit Director
G

Bona fide gift

Common Stock
Disposed (D)40,0000—10,500Direct (D) No— Open filing 0001193125-26-102632 Read from the filing’s XML Dispute this row
2026-03-10 Filed 2026-03-11Parikh Asit Director
G

Bona fide gift

Common Stock
Acquired (A)40,0000—120,500Indirect (I) by TrustNo
F1
  • F1 Reflects shares transferred for no consideration to a trust for the benefit of the Reporting Person's spouse and for which the Reporting Person serves as trustee.
Open filing 0001193125-26-102632 Read from the filing’s XML Dispute this row
2026-02-27 Filed 2026-03-03Breedlove Robert Charles Officer: Principal Accounting Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)13,0000—60,068Direct (D) No
F1
  • F1 Represents restricted stock units (RSUs) granted on February 27, 2026. 1/3 of the total number of RSUs granted vest on each of the first three anniversaries of February 27, 2026, the vesting commencement date, subject to the Reporting Person's continued service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
Open filing 0001193125-26-088730 Read from the filing’s XML Dispute this row
2026-02-27 Filed 2026-03-03Breedlove Robert Charles Officer: Principal Accounting Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)2,7900—62,858Direct (D) No
F2
  • F2 Represents shares issued upon vesting of performance stock units granted to the reporting person on February 27, 2025 based on the achievement of performance criteria determined to be satisfied on February 27, 2026.
Open filing 0001193125-26-088730 Read from the filing’s XML Dispute this row
2026-02-27 Filed 2026-03-03Breedlove Robert Charles Officer: Principal Accounting Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)96412.56
12,107.84

Derived: shares × price per share. Exact value 12107.84.

61,894Direct (D) No
F3
  • F3 Represents shares underlying the performance stock units that were surrendered by the reporting person to the Issuer in satisfaction of the Issuer's tax withholding obligation.
Open filing 0001193125-26-088730 Read from the filing’s XML Dispute this row
2026-02-27 Filed 2026-03-03Breedlove Robert Charles Officer: Principal Accounting Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)41412.56
5,199.84

Derived: shares × price per share. Exact value 5199.84.

61,480Direct (D) No
F4
  • F4 Represents shares underlying RSUs that were surrendered by the reporting person to the Issuer upon vesting of such RSU in satisfaction of the Issuer's tax withholding obligation.
Open filing 0001193125-26-088730 Read from the filing’s XML Dispute this row
2026-02-10 Filed 2026-02-12Basta Steven L Director · Officer: President and CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)12,3620—379,592Direct (D) No
F1, F2
  • F1 Represents shares issued upon vesting of performance stock units granted to the reporting person on April 3, 2025 based on the achievement of performance criteria determined to be satisfied on February 10, 2026.
  • F2 Includes 2,410 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2026.
Open filing 0001193125-26-048867 Read from the filing’s XML Dispute this row
2026-02-10 Filed 2026-02-12Basta Steven L Director · Officer: President and CEO
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)6,27712.82
80,471.14

Derived: shares × price per share. Exact value 80471.14.

373,315Direct (D) No
F3
  • F3 Represents shares underlying the performance stock units that were surrendered by the reporting person to the Issuer in satisfaction of the Issuer's tax withholding obligation.
Open filing 0001193125-26-048867 Read from the filing’s XML Dispute this row
2026-02-10 Filed 2026-02-12Cook Anne Marie Officer: Chief Legal Off. Corp. Sec.
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)3,4610—90,195Direct (D) No
F1, F2
  • F1 Represents shares issued upon vesting of performance stock units granted to the reporting person on June 23, 2025 based on the achievement of performance criteria determined to be satisfied on February 10, 2026.
  • F2 Includes 1,722 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2026.
Open filing 0001193125-26-048881 Read from the filing’s XML Dispute this row
2026-02-10 Filed 2026-02-12Cook Anne Marie Officer: Chief Legal Off. Corp. Sec.
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)1,53512.82
19,678.7

Derived: shares × price per share. Exact value 19678.70.

88,660Direct (D) No
F3
  • F3 Represents shares underlying the performance stock units that were surrendered by the reporting person to the Issuer in satisfaction of the Issuer's tax withholding obligation.
Open filing 0001193125-26-048881 Read from the filing’s XML Dispute this row
2026-01-23 Filed 2026-01-27Parikh Asit Director
G

Bona fide gift

Common Stock
Disposed (D)80,5000—50,500Direct (D) No— Open filing 0001193125-26-024600 Read from the filing’s XML Dispute this row
2026-01-23 Filed 2026-01-27Parikh Asit Director
G

Bona fide gift

Common Stock
Acquired (A)80,5000—80,500Indirect (I) by TrustNo
F1, F2
  • F1 Reflects shares transferred for no consideration to a trust for the benefit of the Reporting Person's spouse and for which the Reporting Person serves as trustee.
  • F2 The shares are subject to a lock-up agreement entered into by the Reporting Person in connection with the underwriting agreement dated January 7, 2026 (the Lock-Up Agreement). The trust has agreed in writing to be bound by the same terms described in the Lock-Up Agreement to the extent and for the duration that such terms remain in effect at the time of the transfer.
Open filing 0001193125-26-024600 Read from the filing’s XML Dispute this row
2026-01-21 Filed 2026-01-23Breedlove Robert Charles Officer: Principal Accounting Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)77613.61
10,561.36

Derived: shares × price per share. Exact value 10561.36.

47,068Direct (D) No
F1
  • F1 Represents shares underlying the restricted stock units that were surrendered by the reporting person to the Issuer in satisfaction of the Issuer's tax withholding obligation.
Open filing 0001193125-26-021164 Read from the filing’s XML Dispute this row
2026-01-13 Filed 2026-01-15Parikh Asit Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)8,75010.3
90,125

Derived: shares × price per share. Exact value 90125.0.

131,000Direct (D) No— Open filing 0001193125-26-014187 Read from the filing’s XML Dispute this row
2026-01-13 Filed 2026-01-15Parikh Asit Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Common Stock (Right to Buy) — underlying Common Stock (8,750) — exercise price 10.3
Disposed (D)8,7500—0Direct (D) No— Open filing 0001193125-26-014187 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-02Narula Sanjeev Officer: Chief Financial Bus. Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)82,7150—226,715Direct (D) No
F1
  • F1 Represents restricted stock units (RSUs) granted on January 2, 2026. 1/3 of the total number of RSUs granted vest on each of the first three anniversaries of January 2, 2026, the vesting commencement date (the Vesting Commencement Date), subject to the Reporting Person's continued service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
Open filing 0001193125-26-001123 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-02Narula Sanjeev Officer: Chief Financial Bus. Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (42,848) — exercise price 15.71
Acquired (A)42,8480—42,848Direct (D) No
F2
  • F2 1/48th of the total number of shares of common stock subject to the option vest monthly following the Vesting Commencement Date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.
Open filing 0001193125-26-001123 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-02Basta Steven L Director · Officer: President and CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)251,0340—364,820Direct (D) No
F1
  • F1 Represents restricted stock units (RSUs) granted on January 2, 2026. 1/3 of the total number of RSUs granted vest on each of the first three anniversaries of January 2, 2026, the vesting commencement date (the Vesting Commencement Date), subject to the Reporting Person's continued service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
Open filing 0001193125-26-001127 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-02Basta Steven L Director · Officer: President and CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (226,156) — exercise price 15.71
Acquired (A)226,1560—221,156Direct (D) No
F2
  • F2 1/48th of the total number of shares of common stock subject to the option vest monthly following the Vesting Commencement Date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.
Open filing 0001193125-26-001127 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-02Cook Anne Marie Officer: Chief Legal Off. Corp. Sec.
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)75,3450—85,012Direct (D) No
F1
  • F1 Represents restricted stock units (RSUs) granted on January 2, 2026. 1/3 of the total number of RSUs granted vest on each of the first three anniversaries of January 2, 2026, the vesting commencement date (the Vesting Commencement Date), subject to the Reporting Person's continued service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
Open filing 0001193125-26-001125 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-02Cook Anne Marie Officer: Chief Legal Off. Corp. Sec.
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (67,878) — exercise price 15.71
Acquired (A)67,8780—67,878Direct (D) No
F2
  • F2 1/48th of the total number of shares of common stock subject to the option vest monthly following the Vesting Commencement Date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.
Open filing 0001193125-26-001125 Read from the filing’s XML Dispute this row
2025-12-19 Filed 2025-12-23Parikh Asit Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)8,75010.3
90,125

Derived: shares × price per share. Exact value 90125.0.

122,250Direct (D) No— Open filing 0001193125-25-331104 Read from the filing’s XML Dispute this row
2025-12-19 Filed 2025-12-23Parikh Asit Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Common Stock (Right to Buy) — underlying Common Stock (8,750) — exercise price 10.3
Disposed (D)8,7500—8,750Direct (D) No— Open filing 0001193125-25-331104 Read from the filing’s XML Dispute this row
2025-12-18 Filed 2025-12-19Breedlove Robert Charles Officer: Principal Accounting Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)23016.28
3,744.4

Derived: shares × price per share. Exact value 3744.40.

47,844Direct (D) No
F1
  • F1 Represents shares underlying the restricted stock units that were surrendered by the reporting person to the Issuer in satisfaction of the Issuer's tax withholding obligation.
Open filing 0001193125-25-327135 Read from the filing’s XML Dispute this row
2025-12-17 Filed 2025-12-19Basta Steven L Director · Officer: President and CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)62,0380—145,288Direct (D) No
F1
  • F1 Represents shares issued upon vesting of performance stock units granted to the reporting person on April 3, 2025 based on the achievement of performance criteria determined to be satisfied on December 17, 2025.
Open filing 0001193125-25-327126 Read from the filing’s XML Dispute this row
2025-12-17 Filed 2025-12-19Basta Steven L Director · Officer: President and CEO
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)31,50215.36
483,870.72

Derived: shares × price per share. Exact value 483870.72.

113,786Direct (D) No
F2
  • F2 Represents shares underlying the performance stock units that were surrendered by the reporting person to the Issuer in satisfaction of the Issuer's tax withholding obligation.
Open filing 0001193125-25-327126 Read from the filing’s XML Dispute this row
2025-12-17 Filed 2025-12-19Cook Anne Marie Officer: Chief Legal Off. Corp. Sec.
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)17,3700—17,370Direct (D) No
F1
  • F1 Represents shares issued upon vesting of performance stock units granted to the reporting person on June 23, 2025 based on the achievement of performance criteria determined to be satisfied on December 17, 2025.
Open filing 0001193125-25-327131 Read from the filing’s XML Dispute this row
2025-12-17 Filed 2025-12-19Cook Anne Marie Officer: Chief Legal Off. Corp. Sec.
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)7,70315.36
118,318.08

Derived: shares × price per share. Exact value 118318.08.

9,667Direct (D) No
F2
  • F2 Represents shares underlying the performance stock units that were surrendered by the reporting person to the Issuer in satisfaction of the Issuer's tax withholding obligation.
Open filing 0001193125-25-327131 Read from the filing’s XML Dispute this row
2025-11-28 Filed 2025-12-02Basta Steven L Director · Officer: President and CEO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)90,0000—131,625Direct (D) No— Open filing 0001193125-25-305575 Read from the filing’s XML Dispute this row
2025-11-28 Filed 2025-12-02Basta Steven L Director · Officer: President and CEO
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)48,37515.62
755,617.5

Derived: shares × price per share. Exact value 755617.50.

83,250Direct (D) No
F1
  • F1 Represents shares underlying the performance stock units that were surrendered by the reporting person to the Issuer in satisfaction of the Issuer's tax withholding obligation.
Open filing 0001193125-25-305575 Read from the filing’s XML Dispute this row
2025-11-28 Filed 2025-12-02Basta Steven L Director · Officer: President and CEO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Performance Shares — underlying Common Stock (90,000) — exercise price 0
Disposed (D)90,0000—180,000Direct (D) No
F2, F3
  • F2 Each performance stock unit represents a contingent right to receive one share of common stock of the Issuer.
  • F3 On April 3, 2025, the reporting person was granted 360,000 performance stock units, of which 90,000 vested on September 25, 2025 and an additional 90,000 vested on November 28, 2025, in each case due to the achievement of the applicable stock price hurdle. The remaining performance stock units will vest based on the achievement of stock price hurdles over a period of four years following the grant date, subject to the reporting person's continued service through the date each such stock price hurdle is achieved.
Open filing 0001193125-25-305575 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,925 filings read, the latest filed 2026-11-19. Prior quarter ending 2026-06-30: 9,176 filings read.

Showing 1–50 of 173

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
Frazier Life Sciences Management, L.P. 12,466,489 SH91,005,370 dollarsUnchanged Prior quarter: 12,466,489Open filing 0001892134-26-000007 Filed 2026-11-16 Dispute this row
Medicxi Ventures Management (Jersey) Ltd Partly reported under another manager7,464,572 SH54,491,376 dollarsUnchanged Prior quarter: 7,464,572Open filing 0001193125-26-442882 Filed 2026-11-02 Dispute this row
BlackRock, Inc. Partly reported under another manager5,246,260 SH38,297,700 dollarsHigher by 721,131 Prior quarter: 4,525,129Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row
Carlyle Group Inc. Partly reported under another manager3,496,808 SH25,526,698 dollarsUnchanged Prior quarter: 3,496,808Open filing 0000898432-26-000769 Filed 2026-11-06 Dispute this row
WASATCH ADVISORS LP Partly reported under another manager2,942,432 SH21,479,754 dollarsHigher by 1,635,185 Prior quarter: 1,307,247Open filing 0000814133-26-000137 Filed 2026-10-13 Dispute this row
VANGUARD CAPITAL MANAGEMENT LLC 2,735,113 SH19,966,325 dollarsHigher by 78,169 Prior quarter: 2,656,944Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row
FRANKLIN TEMPLETON INC Partly reported under another manager2,406,391 SH13,668,301 dollarsHigher by 435,563 Prior quarter: 1,970,828Open filing 0000038777-26-000291 Filed 2026-11-12 Dispute this row
MILLENNIUM MANAGEMENT LLC 2,400,970 SH17,527,081 dollarsLower by 974,864 Prior quarter: 3,375,834Open filing 0001273087-26-000011 Filed 2026-11-16 Dispute this row
GWK Investment Management, LLC 2,128,822 SH15,540 dollarsLower by 38,016 Prior quarter: 2,166,838Open filing 0001082917-26-000006 Filed 2026-11-10 Dispute this row
683 Capital Management, LLC Partly reported under another manager2,000,000 SH14,600,000 dollarsHigher by 150,000 Prior quarter: 1,850,000Open filing 0001404574-26-000027 Filed 2026-11-16 Dispute this row
STATE STREET CORP Partly reported under another manager1,997,876 SH14,584,495 dollarsHigher by 411,553 Prior quarter: 1,586,323Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row
NEA Management Company, LLC 1,960,169 SH14,309,234 dollarsUnchanged Prior quarter: 1,960,169Open filing 0001072613-26-000901 Filed 2026-11-16 Dispute this row
Catalys Pacific, LLC 1,882,039 SH13,738,885 dollarsHigher by 388,185 Prior quarter: 1,493,854Open filing 0001104659-26-120524 Filed 2026-10-30 Dispute this row
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. Partly reported under another manager1,835,701 SH13,400,617 dollarsHigher by 372,963 Prior quarter: 1,462,738Open filing 0000905148-26-004861 Filed 2026-11-16 Dispute this row
Point72 Asset Management, L.P. 1,501,268 SH10,959,256 dollarsHigher by 479,075 Prior quarter: 1,022,193Open filing 0000919574-26-008126 Filed 2026-11-16 Dispute this row
GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager1,334,654 SH9,744,614 dollarsHigher by 18,967 Prior quarter: 1,315,687Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row
Propel Bio Management, LLC Partly reported under another manager1,105,913 SH8,073,165 dollarsHigher by 55,555 Prior quarter: 1,050,358Open filing 0001829126-26-012373 Filed 2026-11-13 Dispute this row
AMERIPRISE FINANCIAL INC Partly reported under another manager967,895 SH7,065,634 dollarsHigher by 673,916 Prior quarter: 293,979Open filing 0001193125-26-463125 Filed 2026-11-16 Dispute this row
GOLDMAN SACHS GROUP INC Partly reported under another manager894,675 SH6,531,127 dollarsLower by 883,357 Prior quarter: 1,778,032Open filing 0000886982-26-000647 Filed 2026-11-16 Dispute this row
Trexquant Investment LP Partly reported under another manager855,542 SH6,245,457 dollarsHigher by 681,658 Prior quarter: 173,884Open filing 0001633445-26-000008 Filed 2026-11-16 Dispute this row
Ensign Peak Advisors, Inc 813,983 SH5,942,076 dollarsLower by 237,930 Prior quarter: 1,051,913Open filing 0001454984-26-000011 Filed 2026-11-12 Dispute this row
HSBC HOLDINGS PLC Partly reported under another manager812,913 SH5,943,298 dollarsHigher by 103,218 Prior quarter: 709,695Open filing 0000873630-26-000005 Filed 2026-11-16 Dispute this row
VANGUARD PORTFOLIO MANAGEMENT LLC 679,320 SH4,959,036 dollarsLower by 117,311 Prior quarter: 796,631Open filing 0002100121-26-001150 Filed 2026-11-13 Dispute this row
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 490,308 SH3,579,248 dollarsHigher by 71,214 Prior quarter: 419,094Open filing 0000884546-26-000417 Filed 2026-11-16 Dispute this row
NORTHERN TRUST CORP Partly reported under another manager467,802 SH3,414,955 dollarsHigher by 9,501 Prior quarter: 458,301Open filing 0000073124-26-000067 Filed 2026-11-16 Dispute this row
CITADEL ADVISORS LLC Option: Call Partly reported under another manager451,900 SH3,298,870 dollarsLower by 28,900 Prior quarter: 480,800Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row
TWO SIGMA INVESTMENTS, LP 423,613 SH3,092,375 dollarsLower by 95,463 Prior quarter: 519,076Open filing 0000899140-26-001341 Filed 2026-11-16 Dispute this row
StepStone Group LP 422,085 SH3,081,221 dollarsUnchanged Prior quarter: 422,085Open filing 0001193125-26-465186 Filed 2026-11-17 Dispute this row
VANGUARD FIDUCIARY TRUST CO 394,315 SH2,878,500 dollarsHigher by 39,742 Prior quarter: 354,573Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row
Hennion Walsh Asset Management, Inc. 392,392 SH2,864,462 dollarsHigher by 65,114 Prior quarter: 327,278Open filing 0002000324-26-005579 Filed 2026-10-13 Dispute this row
UBS Group AG Partly reported under another manager376,377 SH2,747,553 dollarsHigher by 171,804 Prior quarter: 204,573Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
Woodline Partners LP 369,357 SH2,696,306 dollarsHigher by 305 Prior quarter: 369,052Open filing 0001172661-26-005063 Filed 2026-11-16 Dispute this row
CITADEL ADVISORS LLC Partly reported under another manager343,670 SH2,508,791 dollarsHigher by 158,769 Prior quarter: 184,901Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row
Jones Hill Capital LP 276,830 SH2,020,859 dollarsHigher by 115,344 Prior quarter: 161,486Open filing 0002102314-26-000006 Filed 2026-11-13 Dispute this row
JPMORGAN CHASE CO Partly reported under another manager273,767 SH2,014,925 dollarsLower by 1,484 Prior quarter: 275,251Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row
XTX Topco Ltd Partly reported under another manager249,556 SH1,821,759 dollarsHigher by 113,724 Prior quarter: 135,832Open filing 0001828301-26-000009 Filed 2026-11-16 Dispute this row
Simplify Asset Management Inc. 249,267 SH1,819,649 dollarsUnchanged Prior quarter: 249,267Open filing 0001172661-26-004722 Filed 2026-10-27 Dispute this row
GROUP ONE TRADING LLC Option: Call 245,200 SH1,789,960 dollarsHigher by 89,600 Prior quarter: 155,600Open filing 0000932540-26-000017 Filed 2026-11-10 Dispute this row
D. E. Shaw Co., Inc. Partly reported under another manager241,980 SH1,766,453 dollarsHigher by 146,320 Prior quarter: 95,660Open filing 0001104659-26-128287 Filed 2026-11-16 Dispute this row
JACOBS LEVY EQUITY MANAGEMENT, INC 227,955 SH1,664,072 dollarsNot in the prior quarter’s filings read Open filing 0000884414-26-000004 Filed 2026-11-16 Dispute this row
BNP PARIBAS FINANCIAL MARKETS Partly reported under another manager196,286 SH1,432,888 dollarsHigher by 187,594 Prior quarter: 8,692Open filing 0001166588-26-000012 Filed 2026-11-12 Dispute this row
NewEdge Advisors, LLC 189,195 SH1,381,124 dollarsLower by 14,767 Prior quarter: 203,962Open filing 0001213900-26-119695 Filed 2026-11-13 Dispute this row
WELLINGTON MANAGEMENT GROUP LLP Partly reported under another manager180,214 SH1,315,562 dollarsHigher by 47,930 Prior quarter: 132,284Open filing 0000902219-26-000323 Filed 2026-11-16 Dispute this row
DIADEMA PARTNERS LP 179,950 SH1,313,635 dollarsHigher by 50,000 Prior quarter: 129,950Open filing 0001892688-26-000170 Filed 2026-11-16 Dispute this row
SUSQUEHANNA INTERNATIONAL GROUP, LLP Option: Call Partly reported under another manager163,400 SH1,192,820 dollarsLower by 46,900 Prior quarter: 210,300Open filing 0001446194-26-000009 Filed 2026-11-16 Dispute this row
Virtus Investment Advisers, LLC Partly reported under another manager162,536 SH1,186,513 dollarsHigher by 50,397 Prior quarter: 112,139Open filing 0000019481-26-000011 Filed 2026-11-12 Dispute this row
Schonfeld Strategic Advisors LLC 160,104 SH1,168,757 dollarsNot in the prior quarter’s filings read Open filing 0001665241-26-000003 Filed 2026-11-16 Dispute this row
BANK OF AMERICA CORP /DE/ Partly reported under another manager157,066 SH1,146,582 dollarsHigher by 6,051 Prior quarter: 151,015Open filing 0000070858-26-000589 Filed 2026-11-16 Dispute this row
Bank of New York Mellon Corp Partly reported under another manager156,308 SH1,141,049 dollarsHigher by 3,995 Prior quarter: 152,313Open filing 0001390777-26-000121 Filed 2026-11-05 Dispute this row
Squarepoint Ops LLC Partly reported under another manager140,601 SH1,026,387 dollarsHigher by 109,006 Prior quarter: 31,595Open filing 0001642575-26-000012 Filed 2026-11-09 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • SummitTX Capital, L.P. 789,550 SH
  • MARSHALL WACE, LLP 666,090 SH
  • EcoR1 Capital, LLC 625,000 SH
  • PERCEPTIVE ADVISORS LLC 532,000 SH
  • Sixth Street Partners Management Company, L.P. 419,094 SH
  • JANE STREET GROUP, LLC 212,706 SH
  • Avidity Partners Management LP 200,000 SH
  • Opaleye Management Inc. 185,589 SH
  • Stratos Wealth Partners, LTD. 100,000 SH
  • Stonepine Capital Management, LLC 85,010 SH
  • ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 77,316 SH
  • Birchview Capital, LP 55,000 SH
  • NOMURA HOLDINGS INC 49,100 SH
  • Man Group plc 48,679 SH
  • NOMURA HOLDINGS INC 40,000 SH
  • Y-Intercept (Hong Kong) Ltd 39,845 SH
  • ALLSTATE CORP 32,875 SH
  • CITADEL ADVISORS LLC 31,100 SH
  • GSA CAPITAL PARTNERS LLP 30,138 SH
  • Caption Management, LLC 24,000 SH
  • Jupiter Topco LLC 21,500 SH
  • State of Wyoming 17,639 SH
  • LAZARD ASSET MANAGEMENT LLC 14,671 SH
  • TOCQUEVILLE ASSET MANAGEMENT L.P. 12,000 SH
  • INTECH INVESTMENT MANAGEMENT LLC 11,388 SH
  • Fulcrum Asset Management LLP 4,458 SH
  • MERCER GLOBAL ADVISORS INC /ADV 1,337 SH
  • Strategic Wealth Advisors LLC 1,000 SH
  • GROUP ONE TRADING LLC 900 SH
  • MassMutual Private Wealth Trust, FSB 427 SH
  • Truvestments Capital LLC 225 SH
  • Optiver Holding B.V. 90 SH
  • Stone House Investment Management, LLC 8 SH
  • Clearstead Advisors, LLC 5 SH
  • Integrated Wealth Concepts LLC 4 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • Reports for quarters ending before 2013-06-30 were filed as plain text and are not read.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
Frazier Life Sciences Public Fund, L.P. Common Stock, $0.0001 par value per share6.55,323,356.0010/29/2026 Filed 2026-11-02SCHEDULE 13D/AAmendment 12Open filing 0001231919-26-001523 Dispute this row
FHMLSP, L.P. Common Stock, $0.0001 par value per share6.55,323,356.0010/29/2026 Filed 2026-11-02SCHEDULE 13D/AAmendment 12Open filing 0001231919-26-001523 Dispute this row
FHMLSP, L.L.C. Common Stock, $0.0001 par value per share6.55,323,356.0010/29/2026 Filed 2026-11-02SCHEDULE 13D/AAmendment 12Open filing 0001231919-26-001523 Dispute this row
Frazier Life Sciences X, L.P. Common Stock, $0.0001 par value per share0.159,403.0010/29/2026 Filed 2026-11-02SCHEDULE 13D/AAmendment 12Open filing 0001231919-26-001523 Dispute this row
FHMLS X, L.P. Common Stock, $0.0001 par value per share0.159,403.0010/29/2026 Filed 2026-11-02SCHEDULE 13D/AAmendment 12Open filing 0001231919-26-001523 Dispute this row
FHMLS X, L.L.C. Common Stock, $0.0001 par value per share0.159,403.0010/29/2026 Filed 2026-11-02SCHEDULE 13D/AAmendment 12Open filing 0001231919-26-001523 Dispute this row
Frazier Life Sciences XI, L.P. Common Stock, $0.0001 par value per share1.2980,286.0010/29/2026 Filed 2026-11-02SCHEDULE 13D/AAmendment 12Open filing 0001231919-26-001523 Dispute this row
FHMLS XI, L.P. Common Stock, $0.0001 par value per share1.2980,286.0010/29/2026 Filed 2026-11-02SCHEDULE 13D/AAmendment 12Open filing 0001231919-26-001523 Dispute this row
FHMLS XI, L.L.C. Common Stock, $0.0001 par value per share1.2980,286.0010/29/2026 Filed 2026-11-02SCHEDULE 13D/AAmendment 12Open filing 0001231919-26-001523 Dispute this row
Frazier Life Sciences IX, L.P. Common Stock, $0.0001 par value per share7.25,827,415.0010/29/2026 Filed 2026-11-02SCHEDULE 13D/AAmendment 12Open filing 0001231919-26-001523 Dispute this row
FHMLS IX, L.P. Common Stock, $0.0001 par value per share7.25,827,415.0010/29/2026 Filed 2026-11-02SCHEDULE 13D/AAmendment 12Open filing 0001231919-26-001523 Dispute this row
FHMLS IX, L.L.C. Common Stock, $0.0001 par value per share7.25,827,416.0010/29/2026 Filed 2026-11-02SCHEDULE 13D/AAmendment 12Open filing 0001231919-26-001523 Dispute this row
Frazier Life Sciences XII, L.P. Common Stock, $0.0001 par value per share0.3276,029.0010/29/2026 Filed 2026-11-02SCHEDULE 13D/AAmendment 12Open filing 0001231919-26-001523 Dispute this row
FHMLS XII, L.P. Common Stock, $0.0001 par value per share0.3276,029.0010/29/2026 Filed 2026-11-02SCHEDULE 13D/AAmendment 12Open filing 0001231919-26-001523 Dispute this row
FHMLS XII, L.L.C. Common Stock, $0.0001 par value per share0.3276,029.0010/29/2026 Filed 2026-11-02SCHEDULE 13D/AAmendment 12Open filing 0001231919-26-001523 Dispute this row
James N. Topper Common Stock, $0.0001 par value per share7.46,013,327.0010/29/2026 Filed 2026-11-02SCHEDULE 13D/AAmendment 12Open filing 0001231919-26-001523 Dispute this row
Patrick J. Heron Common Stock, $0.0001 par value per share7.35,901,756.0010/29/2026 Filed 2026-11-02SCHEDULE 13D/AAmendment 12Open filing 0001231919-26-001523 Dispute this row
Invesco Ltd. Common Stock0.030,562.0009/30/2026 Filed 2026-11-10SCHEDULE 13G/AAmendment 5Open filing 0000914208-26-000448 Dispute this row
BlackRock, Inc. Common Stock5.54,378,64706/30/2026 Filed 2026-07-29SCHEDULE 13GOpen filing 0002012383-26-002854 Dispute this row
Millennium Management LLC Common Stock, par value $0.0001 per share4.23,375,834.0006/30/2026 Filed 2026-07-20SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-085122 Dispute this row
Millennium Group Management LLC Common Stock, par value $0.0001 per share4.23,375,834.0006/30/2026 Filed 2026-07-20SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-085122 Dispute this row
Israel A. Englander Common Stock, par value $0.0001 per share4.23,375,834.0006/30/2026 Filed 2026-07-20SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-085122 Dispute this row
Millennium Management LLC Common Stock, par value $0.0001 per share5.34,178,411.0003/06/2026 Filed 2026-03-12SCHEDULE 13GOpen filing 0001104659-26-027124 Dispute this row
Millennium Group Management LLC Common Stock, par value $0.0001 per share5.34,178,411.0003/06/2026 Filed 2026-03-12SCHEDULE 13GOpen filing 0001104659-26-027124 Dispute this row
Israel A. Englander Common Stock, par value $0.0001 per share5.34,178,411.0003/06/2026 Filed 2026-03-12SCHEDULE 13GOpen filing 0001104659-26-027124 Dispute this row
Integrated Core Strategies (US) LLC Common Stock, par value $0.0001 per share1.61,255,161.0012/31/2025 Filed 2026-01-27SCHEDULE 13G/AAmendment 3Open filing 0001104659-26-007000 Dispute this row
Millennium Management LLC Common Stock, par value $0.0001 per share2.72,082,180.0012/31/2025 Filed 2026-01-27SCHEDULE 13G/AAmendment 3Open filing 0001104659-26-007000 Dispute this row
Millennium Group Management LLC Common Stock, par value $0.0001 per share2.72,082,180.0012/31/2025 Filed 2026-01-27SCHEDULE 13G/AAmendment 3Open filing 0001104659-26-007000 Dispute this row
Israel A. Englander Common Stock, par value $0.0001 per share2.72,082,180.0012/31/2025 Filed 2026-01-27SCHEDULE 13G/AAmendment 3Open filing 0001104659-26-007000 Dispute this row
Frazier Life Sciences Public Fund, L.P. Common Stock, $0.0001 par value per share7.55,323,356.0011/01/2025 Filed 2025-11-04SCHEDULE 13D/AAmendment 11Open filing 0001231919-25-000418 Dispute this row
FHMLSP, L.P. Common Stock, $0.0001 par value per share7.55,323,356.0011/01/2025 Filed 2025-11-04SCHEDULE 13D/AAmendment 11Open filing 0001231919-25-000418 Dispute this row
FHMLSP, L.L.C. Common Stock, $0.0001 par value per share7.55,323,356.0011/01/2025 Filed 2025-11-04SCHEDULE 13D/AAmendment 11Open filing 0001231919-25-000418 Dispute this row
Frazier Life Sciences X, L.P. Common Stock, $0.0001 par value per share0.159,403.0011/01/2025 Filed 2025-11-04SCHEDULE 13D/AAmendment 11Open filing 0001231919-25-000418 Dispute this row
FHMLS X, L.P. Common Stock, $0.0001 par value per share0.159,403.0011/01/2025 Filed 2025-11-04SCHEDULE 13D/AAmendment 11Open filing 0001231919-25-000418 Dispute this row
FHMLS X, L.L.C. Common Stock, $0.0001 par value per share0.159,403.0011/01/2025 Filed 2025-11-04SCHEDULE 13D/AAmendment 11Open filing 0001231919-25-000418 Dispute this row
Frazier Life Sciences XI, L.P. Common Stock, $0.0001 par value per share1.4980,286.0011/01/2025 Filed 2025-11-04SCHEDULE 13D/AAmendment 11Open filing 0001231919-25-000418 Dispute this row
FHMLS XI, L.P. Common Stock, $0.0001 par value per share1.4980,286.0011/01/2025 Filed 2025-11-04SCHEDULE 13D/AAmendment 11Open filing 0001231919-25-000418 Dispute this row
FHMLS XI, L.L.C. Common Stock, $0.0001 par value per share1.4980,286.0011/01/2025 Filed 2025-11-04SCHEDULE 13D/AAmendment 11Open filing 0001231919-25-000418 Dispute this row
Frazier Life Sciences IX, L.P. Common Stock, $0.0001 par value per share8.25,827,415.0011/01/2025 Filed 2025-11-04SCHEDULE 13D/AAmendment 11Open filing 0001231919-25-000418 Dispute this row
FHMLS IX, L.P. Common Stock, $0.0001 par value per share8.25,827,415.0011/01/2025 Filed 2025-11-04SCHEDULE 13D/AAmendment 11Open filing 0001231919-25-000418 Dispute this row
FHMLS IX, L.L.C. Common Stock, $0.0001 par value per share8.25,827,416.0011/01/2025 Filed 2025-11-04SCHEDULE 13D/AAmendment 11Open filing 0001231919-25-000418 Dispute this row
Frazier Life Sciences XII, L.P. Common Stock, $0.0001 par value per share0.4276,029.0011/01/2025 Filed 2025-11-04SCHEDULE 13D/AAmendment 11Open filing 0001231919-25-000418 Dispute this row
FHMLS XII, L.P. Common Stock, $0.0001 par value per share0.4276,029.0011/01/2025 Filed 2025-11-04SCHEDULE 13D/AAmendment 11Open filing 0001231919-25-000418 Dispute this row
FHMLS XII, L.L.C. Common Stock, $0.0001 par value per share0.4276,029.0011/01/2025 Filed 2025-11-04SCHEDULE 13D/AAmendment 11Open filing 0001231919-25-000418 Dispute this row
James N. Topper Common Stock, $0.0001 par value per share8.65,985,327.0011/01/2025 Filed 2025-11-04SCHEDULE 13D/AAmendment 11Open filing 0001231919-25-000418 Dispute this row
Patrick J. Heron Common Stock, $0.0001 par value per share8.45,901,756.0011/01/2025 Filed 2025-11-04SCHEDULE 13D/AAmendment 11Open filing 0001231919-25-000418 Dispute this row
Integrated Core Strategies (US) LLC Common Stock, par value $0.0001 per share5.84,149,826.0009/30/2025 Filed 2025-11-03SCHEDULE 13G/AAmendment 2Open filing 0001104659-25-105568 Dispute this row
Millennium Management LLC Common Stock, par value $0.0001 per share7.15,081,451.0009/30/2025 Filed 2025-11-03SCHEDULE 13G/AAmendment 2Open filing 0001104659-25-105568 Dispute this row
Millennium Group Management LLC Common Stock, par value $0.0001 per share7.15,081,451.0009/30/2025 Filed 2025-11-03SCHEDULE 13G/AAmendment 2Open filing 0001104659-25-105568 Dispute this row
Israel A. Englander Common Stock, par value $0.0001 per share7.15,081,451.0009/30/2025 Filed 2025-11-03SCHEDULE 13G/AAmendment 2Open filing 0001104659-25-105568 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,655,474 filings read, dated 2004-06-14 to 2026-11-19: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
201572,561
2016222,642
2017222,009
2018223,345
2019216,482
2020226,343
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026263,123

Filings made before the SEC required XML are listed, not extracted.

Back to PHATHOM PHARMACEUTICALS, INC.